Our mission is to explore the therapeutic benefits of the keratin molecule—as it is the foundation of organic tissue repair—and provide our products to those who are in greatest need.
Our passions are keratin proteins and peptides, of which we currently manufacture proprietary fractionations that are incorporated into our prescription-only products.
Founded in 2015, Molecular Biologicals is a biotechnology company that provides prescription-only keratin products for Dermatological, Regenerative and Woundcare markets worldwide. Our company is based on a therapeutic keratin platform developed from years of research and supported by patented proprietary manufacturing and processing technologies.
Molecular Biologicals is currently investigating the use of Replicine™ Bioactive Keratin in specific wound types and formulations. We are actively involved in expanding our pipeline of products in high priority access areas with obvious unmet needs, like orphan diseases.
Keroxx, a flowable advanced-wound matrix containing the active ingredient Replicine™ Bioactive Keratin will be available in 2020.